After selling its lead product to Allergan last year for $587.5 million, TARIS Biomedical has pivoted into developing a bladder cancer drug device combination with a $32 million investment.
Taris Biomedical Inc. drummed up $18.3 million in its latest funding round. The Lexington, Mass.-based company said the equity-based B round will support its lidocaine delivery technology developed at MIT to treat bladder conditions. Third Rock Ventures, a new backer for the company, led the round, and previous investors Flagship Ventures, Flybridge Capital Partners and […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.